Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High Efficacy Halts ViiV HIV Prevention Study Early

ViiV Hopes Faster Cabotegravir Approval Will Be The Result

Executive Summary

Prospects have improved for ViiV’s long-acting, injectable cabotegravir to be approved early for HIV prevention after a Phase III trial was stopped early due to efficacy.

You may also be interested in...



ViiV Readies Entry To HIV PrEP Market After Apretude Approval

A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.

Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women

ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.

ViiV Thinks It May Get All-Gender Approval For Cabotegravir For PrEP

Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel